Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers (Q37786422)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 15, 2010

Language	Label	Description	Also known as
English	Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers	scientific article published on September 15, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

object named as

Erik De Clercq

1

0 references

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20826182

9 July 2024

publication date

15 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0163725810001683?httpAccept=text/xml

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

https://api.elsevier.com/content/article/PII:S0163725810001683?httpAccept=text/plain

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

128

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

509-518

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation

1

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

2

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Improving stem cell mobilization strategies: future directions

3

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100.

4

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication

5

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

6

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

7

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

CXCR4 chemokine receptor antagonists: perspectives in SCLC

8

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model

9

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

10

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

11

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells

12

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

The bicyclam AMD3100 story

13

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

14

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

15

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

16

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

17

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

18

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

19

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures

20

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

21

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

HIV entry inhibitors.

22

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

23

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

24

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

A novel CXCR4 antagonist for hematopoietic stem cell mobilization

25

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

26

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment

27

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor

28

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

29

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

New agents for mobilizing peripheral blood stem cells.

30

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

31

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma

32

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

33

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

34

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

AMD3100 is a CXCR7 ligand with allosteric agonist properties

35

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.

36

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes.

38

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

39

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

40

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer

41

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide

42

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

43

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

44

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

46

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

47

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Cytokines and hematopoietic stem cell mobilization

48

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

49

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Chemokine-mobilized adult stem cells; defining a better hematopoietic graft

50

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties

51

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions

52

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Differential mobilization of subsets of progenitor cells from the bone marrow

53

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

54

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.

55

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

CXCR4 and mobilization of hematopoietic precursors.

56

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

58

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100.

61

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

62

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

63

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

64

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.

65

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor approved for autologous hematopoietic stem-cell transplantation

66

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists

67

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

68

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells

69

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Advances in mobilization for the optimization of autologous stem cell transplantation

70

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma

71

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors

72

1 reference

10.1016/J.PHARMTHERA.2010.08.009

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2010.08.009

9 July 2024

Identifiers

10.1016/J.PHARMTHERA.2010.08.009

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37786422&oldid=2199116158"